{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T16:21:14Z","timestamp":1766074874692,"version":"3.48.0"},"reference-count":30,"publisher":"Walter de Gruyter GmbH","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_jbcpp-2024-0104_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study aims to assess the prevalence, characteristics, and risk factors of potential QT-prolonging drug\u2013drug interactions (pQT-DDIs) in cancer patients, including identifying drug combinations contributing to QT prolongation and key predictors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jbcpp-2024-0104_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this hospital-based, cross-sectional observational study, all types of cancer patients, irrespective of age or sex, were included over 1\u00a0year. pQT-DDIs were identified using four drug interaction checker software tools. Predictors were analyzed using univariate logistic regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jbcpp-2024-0104_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 1,331 cancer patients were included. The prevalence of pQT-DDIs was 67.6\u202f%. Of these, 606 (45.5\u202f%) had 1\u20132\u00a0pQT-DDIs, 126 (9.5\u202f%) had 3\u20134, and 78 (5.9\u202f%) had 5\u20136. Overall, 163 drug combinations were identified as causing QT prolongation; 122 were detected by\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/Drugs.com\">Drugs.com<\/jats:ext-link>\n                      . Significant predictors included &gt;8 drugs prescribed (OR=6.46; CI=4.87\u20138.56; p&lt;0.0001), &gt;2 anticancer drugs (OR=1.68; CI=1.14\u20132.46; p=0.008), &gt;6 adjuvant drugs (OR=6.83; CI=5.17\u20139.03; p&lt;0.0001), solid cancers (OR=6.59; CI=4.59\u20138.80; p&lt;0.0001), and cytotoxic drug use (OR=2.40; CI=1.52\u20133.77; p=0.0001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jbcpp-2024-0104_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>There is a high prevalence of pQT-DDIs in cancer patients. Those receiving multiple anticancer and adjuvant drugs are at higher risk. Routine interaction screening is recommended before chemotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/jbcpp-2024-0104","type":"journal-article","created":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T12:56:44Z","timestamp":1754917004000},"page":"373-381","source":"Crossref","is-referenced-by-count":0,"title":["A cross-sectional observational study of the prevalence and characterization of potential QT-prolonging drug\u2012drug interactions in oncological outpatients"],"prefix":"10.1515","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3921-0449","authenticated-orcid":false,"given":"Akash","family":"Agnihotri","sequence":"first","affiliation":[{"name":"Department of Pharmacology , Amrita School of Medicine , Amrita Vishwa Vidyapeetham , Faridabad , Haryana , India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biswadeep","family":"Das","sequence":"additional","affiliation":[{"name":"Department of Pharmacology , All India Institute of Medical Sciences , Rishikesh , Uttarakhand , India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachin","family":"Manocha","sequence":"additional","affiliation":[{"name":"Department of Pharmacology , Amrita School of Medicine , Amrita Vishwa Vidyapeetham , Faridabad , Haryana , India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manjunath","family":"Bidarolli","sequence":"additional","affiliation":[{"name":"Department of Pharmacology , Amrita School of Medicine , Amrita Vishwa Vidyapeetham , Faridabad , Haryana , India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bharati","family":"Vashisht","sequence":"additional","affiliation":[{"name":"Department of Computer Science , Government College for Girls , Gurugram , Haryana , India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"2025121816170547697_j_jbcpp-2024-0104_ref_001","doi-asserted-by":"crossref","unstructured":"Siegel, RL, Giaquinto, AN, Jemal, A. Cancer statistics, 2024. CA Cancer J Clin 2024;74:12\u201349. https:\/\/doi.org\/10.3322\/caac.21820.","DOI":"10.3322\/caac.21820"},{"key":"2025121816170547697_j_jbcpp-2024-0104_ref_002","doi-asserted-by":"crossref","unstructured":"Wondm, SA, Tamene, FB, Gubae, K, Dagnew, SB, Worku, AA, Belachew, EA, et al.. Potential drug\u2013drug interaction and its determinants among patients with cancer receiving chemotherapy in oncology centres of northwest Ethiopia: an institutional-based cross-sectional study. BMJ Open 2023;13:e077863. https:\/\/doi.org\/10.1136\/bmjopen-2023-077863.","DOI":"10.1136\/bmjopen-2023-077863"},{"key":"2025121816170547697_j_jbcpp-2024-0104_ref_003","doi-asserted-by":"crossref","unstructured":"van Leeuwen, RWF, Brundel, DHS, Neef, C, van Gelder, T, Mathijssen, RHJ, Burger, DM, et al.. Prevalence of potential drug\u2013drug interactions in cancer patients treated with oral anticancer drugs. Br J Cancer 2013;108:1071\u20138. https:\/\/doi.org\/10.1038\/bjc.2013.48.","DOI":"10.1038\/bjc.2013.48"},{"key":"2025121816170547697_j_jbcpp-2024-0104_ref_004","doi-asserted-by":"crossref","unstructured":"Cuni, R, Parrini, I, Asteggiano, R, Conte, MR. Targeted cancer therapies and QT interval prolongation: unveiling the mechanisms underlying arrhythmic complications and the need for risk stratification strategies. Clin Drug Invest 2017;37:121\u201334. https:\/\/doi.org\/10.1007\/s40261-016-0460-5.","DOI":"10.1007\/s40261-016-0460-5"},{"key":"2025121816170547697_j_jbcpp-2024-0104_ref_005","doi-asserted-by":"crossref","unstructured":"Porta-S\u00e1nchez, A, Gilbert, C, Spears, D, Amir, E, Chan, J, Nanthakumar, K, et al.. Incidence, diagnosis, and management of QT prolongation induced by cancer therapies: a systematic review. J\u00a0Am Heart Assoc Cardiovasc Cerebrovasc Dis 2017;6:e007724. https:\/\/doi.org\/10.1161\/jaha.117.007724.","DOI":"10.1161\/JAHA.117.007724"},{"key":"2025121816170547697_j_jbcpp-2024-0104_ref_006","doi-asserted-by":"crossref","unstructured":"Giraud, EL, Ferrier, KRM, Lankheet, NAG, Desar, IME, Steeghs, N, Beukema, RJ, et al.. The QT interval prolongation potential of anticancer and supportive drugs: a comprehensive overview. Lancet Oncol 2022;23:e406\u2013415. https:\/\/doi.org\/10.1016\/s1470-2045-22-00221-2.","DOI":"10.1016\/S1470-2045(22)00221-2"},{"key":"2025121816170547697_j_jbcpp-2024-0104_ref_007","doi-asserted-by":"crossref","unstructured":"Khan, Q, Ismail, M, Khan, S. Frequency, characteristics and risk factors of QT interval prolonging drugs and drug-drug interactions in cancer patients: a multicenter study. BMC Pharmacol Toxicol 2017;18:75. https:\/\/doi.org\/10.1186\/s40360-017-0181-2.","DOI":"10.1186\/s40360-017-0181-2"},{"key":"2025121816170547697_j_jbcpp-2024-0104_ref_008","doi-asserted-by":"crossref","unstructured":"Smithburger, PL, Kane-Gill, SL, Seybert, AL. Drug-drug interactions in cardiac and cardiothoracic intensive care units. Drug Saf 2010;33:879\u201388. https:\/\/doi.org\/10.2165\/11532340-000000000-00000.","DOI":"10.2165\/11532340-000000000-00000"},{"key":"2025121816170547697_j_jbcpp-2024-0104_ref_009","doi-asserted-by":"crossref","unstructured":"Agnihotri, A, Ramasubbu, SK, Bandyopadhyay, A, Bidarolli, M, Nath, UK, Das, B, et al.. Prevalence, attributes, and risk factors of QT-Interval-Prolonging drugs and potential drug-drug interactions in cancer patients: a prospective study in a tertiary care hospital. Cureus 2024;16:e60492. https:\/\/doi.org\/10.7759\/cureus.60492.","DOI":"10.7759\/cureus.60492"},{"key":"2025121816170547697_j_jbcpp-2024-0104_ref_010","doi-asserted-by":"crossref","unstructured":"van Leeuwen, RWF, Swart, EL, Boven, E, Boom, FA, Schuitenmaker, MG, Hugtenburg, JG, et al.. Potential drug interactions in cancer therapy: a prevalence study using an advanced screening method. Ann Oncol Off J Eur Soc Med Oncol 2011;22:2334\u201341. https:\/\/doi.org\/10.1093\/annonc\/mdq761.","DOI":"10.1093\/annonc\/mdq761"},{"key":"2025121816170547697_j_jbcpp-2024-0104_ref_011","doi-asserted-by":"crossref","unstructured":"Kim, P, Masha, L, Olson, A, Iliescu, C, Karimzad, K, Hassan, S, et al.. QT prolongation in cancer patients. Front Cardiovasc Med 2021;8:613625. https:\/\/doi.org\/10.3389\/fcvm.2021.613625.","DOI":"10.3389\/fcvm.2021.613625"},{"key":"2025121816170547697_j_jbcpp-2024-0104_ref_012","doi-asserted-by":"crossref","unstructured":"Das, B, Rawat, VS, Ramasubbu, SK, Kumar, B. Frequency, characteristics and nature of risk factors associated with use of QT interval prolonging medications and related drug-drug interactions in a cohort of psychiatry patients. Therapie (Paris) 2019;74:599\u2013609. https:\/\/doi.org\/10.1016\/j.therap.2019.03.008.","DOI":"10.1016\/j.therap.2019.03.008"},{"key":"2025121816170547697_j_jbcpp-2024-0104_ref_013","doi-asserted-by":"crossref","unstructured":"Das, B, Ramasubbu, SK, Agnihotri, A, Kumar, B, Rawat, VS. Leading 20 drug\u2013drug interactions, polypharmacy, and analysis of the nature of risk factors due to QT interval prolonging drug use and potentially inappropriate psychotropic use in elderly psychiatry outpatients. Ther Adv Cardiovasc Dis 2021;15:https:\/\/doi.org\/10.1177\/17539447211058892, 17539447211058892.","DOI":"10.1177\/17539447211058892"},{"key":"2025121816170547697_j_jbcpp-2024-0104_ref_014","doi-asserted-by":"crossref","unstructured":"Ramasubbu, SK, Mahato, SK, Agnihotri, A, Pasricha, RK, Nath, UK, Das, B, et al.. Prevalence, severity, and nature of risk factors associated with drug-drug interactions in geriatric patients receiving cancer chemotherapy: a prospective study in a tertiary care teaching hospital. Cancer Treat Res Commun 2021;26:100277. https:\/\/doi.org\/10.1016\/j.ctarc.2020.100277.","DOI":"10.1016\/j.ctarc.2020.100277"},{"key":"2025121816170547697_j_jbcpp-2024-0104_ref_015","unstructured":"Drugs.com drug interaction checker. https:\/\/www.drugs.com\/drug_interactions.html [Accessed 31 May 2024]."},{"key":"2025121816170547697_j_jbcpp-2024-0104_ref_016","unstructured":"Epocrates drug interaction checker. https:\/\/www.epocrates.com\/online\/interaction-check [Accessed 31 May 2024]."},{"key":"2025121816170547697_j_jbcpp-2024-0104_ref_017","unstructured":"Medscape drug interaction checker. https:\/\/reference.medscape.com\/drug-interactionchecker [Accessed 31 May 2024]."},{"key":"2025121816170547697_j_jbcpp-2024-0104_ref_018","unstructured":"UpToDate lexicomp drug interaction checker. https:\/\/www.uptodate.com\/drug-interactions\/#di-druglist [Accessed 31 May 2024]."},{"key":"2025121816170547697_j_jbcpp-2024-0104_ref_019","doi-asserted-by":"crossref","unstructured":"van Leeuwen, RWF, Jansman, FGA, van den Bemt, PMLA, de Man, F, Piran, F, Vincenten, I, et al.. Drug-drug interactions in patients treated for cancer: a prospective study on clinical interventions. Ann Oncol Off J Eur Soc Med Oncol 2015;26:992\u20137. https:\/\/doi.org\/10.1093\/annonc\/mdv029.","DOI":"10.1093\/annonc\/mdv029"},{"key":"2025121816170547697_j_jbcpp-2024-0104_ref_020","doi-asserted-by":"crossref","unstructured":"Moghaddas, A, Adib-Majlesi, M, Sabzghabaee, AM, Hajigholami, A, Riechelmann, R. Potential drug\u2013drug interactions in hospitalized cancer patients: a report from the middle-east. J\u00a0Oncol Pharm Pract 2021;27:46\u201353. https:\/\/doi.org\/10.1177\/1078155220910209.","DOI":"10.1177\/1078155220910209"},{"key":"2025121816170547697_j_jbcpp-2024-0104_ref_021","doi-asserted-by":"crossref","unstructured":"Sheikh-Taha, M, Asmar, M. Polypharmacy and severe potential drug-drug interactions among older adults with cardiovascular disease in the United\u00a0States. BMC Geriatr 2021;21:233. https:\/\/doi.org\/10.1186\/s12877-021-02183-0.","DOI":"10.1186\/s12877-021-02183-0"},{"key":"2025121816170547697_j_jbcpp-2024-0104_ref_022","doi-asserted-by":"crossref","unstructured":"Yal\u00e7\u0131n, N, \u00d6zdemir, N, \u00c7ak Esen, HT, \u00c7engel K\u00fclt\u00fcr, SE, Demirkan, K. Potential drug-drug interactions with psychotropic drugs in paediatric inpatients: a cross-sectional study. Int J Clin Pract 2021;75:e14107. https:\/\/doi.org\/10.1111\/ijcp.14107.","DOI":"10.1111\/ijcp.14107"},{"key":"2025121816170547697_j_jbcpp-2024-0104_ref_023","doi-asserted-by":"crossref","unstructured":"Hefner, G, Hahn, M, Hiemke, C, Toto, S, Wolff, J, Roll, SC, et al.. Pharmacodynamic drug\u2013drug interactions of QT-prolonging drugs in hospitalized psychiatric patients. J\u00a0Neural Transm 2021;128:243\u201352. https:\/\/doi.org\/10.1007\/s00702-020-02291-y.","DOI":"10.1007\/s00702-020-02291-y"},{"key":"2025121816170547697_j_jbcpp-2024-0104_ref_024","doi-asserted-by":"crossref","unstructured":"Bjerrum, L, Andersen, M, Petersen, G, Kragstrup, J. Exposure to potential drug interactions in primary health care. Scand J Prim Health Care 2003;21:153\u20138. https:\/\/doi.org\/10.1080\/02813430310001806.","DOI":"10.1080\/02813430310001806"},{"key":"2025121816170547697_j_jbcpp-2024-0104_ref_025","doi-asserted-by":"crossref","unstructured":"Viktil, KK, Blix, HS, Moger, TA, Reikvam, A. Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug-related problems. Br J Clin Pharmacol 2007;63:187\u201395. https:\/\/doi.org\/10.1111\/j.1365-2125.2006.02744.x.","DOI":"10.1111\/j.1365-2125.2006.02744.x"},{"key":"2025121816170547697_j_jbcpp-2024-0104_ref_026","doi-asserted-by":"crossref","unstructured":"Stoll, P, Kopittke, L. Potential drug\u2013drug interactions in hospitalized patients undergoing systemic chemotherapy: a prospective cohort study. Int J Clin Pharm 2015;37:475\u201384. https:\/\/doi.org\/10.1007\/s11096-015-0083-6.","DOI":"10.1007\/s11096-015-0083-6"},{"key":"2025121816170547697_j_jbcpp-2024-0104_ref_027","doi-asserted-by":"crossref","unstructured":"Riechelmann, RP, Moreira, F, Smaletz, \u00d2, Saad, ED. Potential for drug interactions in hospitalized cancer patients. Cancer Chemother Pharmacol 2005;56:286\u201390. https:\/\/doi.org\/10.1007\/s00280-004-0998-4.","DOI":"10.1007\/s00280-004-0998-4"},{"key":"2025121816170547697_j_jbcpp-2024-0104_ref_028","doi-asserted-by":"crossref","unstructured":"Osman, MA, Abdalla, MA, Mohamed, AA, Yousef, BA. Assessment of drug\u2013drug interactions between chemotherapeutic and chronically used medications at Khartoum oncology hospital. Matrix Sci Medica 2020;4:79. https:\/\/doi.org\/10.4103\/mtsm.mtsm-17-20.","DOI":"10.4103\/MTSM.MTSM_17_20"},{"key":"2025121816170547697_j_jbcpp-2024-0104_ref_029","doi-asserted-by":"crossref","unstructured":"Suriyapakorn, B, Chairat, P, Boonyoprakarn, S, Rojanarattanangkul, P, Pisetcheep, W, Hunsakunachai, N, et al.. Comparison of potential drug-drug interactions with metabolic syndrome medications detected by two databases. PLoS One 2019;14:e0225239. https:\/\/doi.org\/10.1371\/journal.pone.0225239.","DOI":"10.1371\/journal.pone.0225239"},{"key":"2025121816170547697_j_jbcpp-2024-0104_ref_030","doi-asserted-by":"crossref","unstructured":"Benjanuwattra, J, Siri-Angkul, N, Chattipakorn, SC, Chattipakorn, N. Doxorubicin and its proarrhythmic effects: a comprehensive review of the evidence from experimental and clinical studies. Pharmacol Res 2020;151:104542. https:\/\/doi.org\/10.1016\/j.phrs.2019.104542.","DOI":"10.1016\/j.phrs.2019.104542"}],"container-title":["Journal of Basic and Clinical Physiology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jbcpp-2024-0104\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jbcpp-2024-0104\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T16:17:53Z","timestamp":1766074673000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jbcpp-2024-0104\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":30,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,11,27]]},"published-print":{"date-parts":[[2025,11,27]]}},"alternative-id":["10.1515\/jbcpp-2024-0104"],"URL":"https:\/\/doi.org\/10.1515\/jbcpp-2024-0104","relation":{},"ISSN":["2191-0286"],"issn-type":[{"type":"electronic","value":"2191-0286"}],"subject":[],"published":{"date-parts":[[2025,8,12]]}}}